Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| ASML | Talen Energy | Pfizer | |
|---|---|---|---|
| Moat rating | wide ASML's FY2025 20-F states it "is currently the world's only manufacturer of EUV lithography systems" — an effective monopoly on the extreme-ultraviolet tools required to pattern leading-edge logic and memory chips. | narrow The FY2025 10-K grounds a real but bounded advantage. Susquehanna produced about 17 TWh in 2025 at an all-in cost of about $27/MWh, and up to 1,920 MW of it is contracted to AWS under a long-term, fixed-price PPA through 2042 'at anticipated premium prices', with deliveries expected to ramp to full volume no later than 2032. The moat is narrow rather than wide because, outside its contracts, the fleet sells into competitive wholesale markets, and the 10-K says that 'unlike regulated utilities, we are not assured of any rate of return on capital investments through a regulated rate structure'. It also concedes that competitors 'may have advantages over us through access to greater resources, newer generation facilities, lower costs, or more experience'. The advantage is also concentrated: Susquehanna has typically been about half of total annual generation. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip The durable advantage rests on decades of proprietary technology and IP — the 20-F describes ASML's April 2025 1,000-watt EUV light source as "built on 25 years of engineering advancements" — reinforced by an exclusive arrangement with Carl Zeiss SMT as its "sole supplier" of the critical optics no rival can source. | cost scale The 10-K says Talen's ability to compete 'is affected primarily by electricity prices, fuel prices, the relative cost of electric generation, and the reliability and availability of generation assets'. The edge it cites is low-cost baseload supply: Susquehanna, the seventh-largest U.S. nuclear plant, produced power at an all-in cost of about $27/MWh in 2025, under NRC licences that expire in 2042 and 2044. The 10-K says natural gas facilities 'often serve as the marginal, price-setting generating units' and that energy margin is influenced by the relationship between electricity and natural gas prices, so a low-cost nuclear unit earns the gap between market price and its own cost. The AWS adjacency is a contract rather than a fleet-wide switching cost, and network effects and IP do not apply. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | clear leader Effectively 100% of the EUV market as the world's only EUV system maker; in the older DUV segment it "compete[s] primarily with Canon and Nikon" yet remains the leading supplier. | at parity Talen calls itself 'a leading independent power producer', but its merchant output is undifferentiated. The 10-K says it sells into PJM capacity auctions and day-ahead and real-time markets against 'other non-utility generators, regulated utilities and their competitive subsidiaries, industrial companies, financial institutions, and other energy marketers', and that some rivals may have greater resources, newer plants or lower costs. Susquehanna's rank as the seventh-largest U.S. nuclear facility shows scale, not market leadership. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | strong FY2025 gross margin of 52.8%, up 1.5 percentage points year over year, with management guiding toward 56-60% by 2030 — consistent with monopoly pricing power on EUV tools. | moderate Pricing power is mixed and sits in the AWS contract. The AWS PPA is fixed-price 'at anticipated premium prices' through 2042, and the 10-K says such large-load contracts 'can lock in meaningful premiums'. The Brandon Shores and H.A. Wagner RMR agreements provide FERC-approved annual fixed-cost payments of $145 million and $35 million from June 1, 2025, each including a performance hold-back, and FERC's approval is under appeal by the Maryland Office of People's Counsel; they give revenue certainty rather than pricing power. The merchant remainder takes market prices. The 10-K says gas units 'often serve as the marginal, price-setting generating units', and the PJM auction imposed a capacity price collar with an approximate minimum and maximum of $175/MWd and $325/MWd for the 2026/2027 and 2027/2028 auctions. In the 2027/2028 auction Talen cleared 8,745 MW at $333.44/MWd. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | ASML is the sole producer of EUV lithography systems, the only tools able to pattern the most advanced logic and memory nodes, with a roadmap "intended to drive affordable scaling to 2030 and beyond" and a High-NA EUV (TWINSCAN EXE) platform on which customers "had run more than 400,000 wafers" by end-2025. That dominance is protected by 25 years of accumulated engineering IP and an exclusive lock on Carl Zeiss SMT optics that competitors cannot replicate. | Talen's advantage comes from one contracted asset. It owns 90% of the 2.5 GW Susquehanna nuclear plant, which produced about 17 TWh in 2025 at about $27/MWh all-in, and it has agreed to supply the adjacent AWS data campus with up to 1,920 MW under a fixed-price PPA through 2042. The rest of its roughly 13.1 GW fleet at the 10-K date (a total that includes its 2.2 GW nuclear share) includes newly acquired H-class combined-cycle gas plants, intermediate and peaking units, the Brandon Shores and H.A. Wagner units kept running under FERC-approved RMR agreements, and about 800 MW of minority interests in three coal-fired plants. Apart from the RMR units, that fleet sells capacity and energy mainly into competitive PJM markets through capacity auctions, spot markets and futures contracts, and the 10-K notes that, 'unlike regulated utilities, we are not assured of any rate of return on capital investments through a regulated rate structure'. The 10-K's 'Talen flywheel' strategy is to repeat the AWS model with other large-load buyers. Until more of the fleet is contracted, the moat stays narrow and concentrated in Susquehanna. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Upstream chokepoint of the AI chip supply chain: every leading-edge logic/DRAM wafer for AI accelerators is patterned on ASML EUV tools, making it the single indispensable equipment supplier to TSMC, Samsung and Intel. | Supplies nuclear power from Susquehanna to Amazon's adjacent AWS data campus, and sells capacity and energy into the PJM grid. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.42 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |